M
any biomarkers have demonstrated clinical utility in oncology for risk assessment, diagnosis, prognosis, prediction of effectiveness or toxicity of a therapy, and posttreatment surveillance. The National Comprehensive Cancer Network (NCCN) developed the NCCN Biomarkers Compendium to present the essential details for biomarkers that are included in the recommendations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
NCCN, a not-for-profit alliance of 23 of the world's leading cancer centers, produces the NCCN Guidelines, which are a widely recognized authority on risk reduction, screening and detection, diagnosis, treatment, and supportive care of cancer. These guidelines are used widely by clinicians around the world to determine appropriate care. The complete library of guidelines comprises 58 guidelines developed in 158 separate algorithms, each with supporting discussion sections and extensive bibliographies. Their format as flow diagrams allows the clinician to readily follow the clinical decision-making steps along the continuum of care from diagnosis through palliation. Developed by more than 950 multidisciplinary disease area specialists from NCCN's 23 member institutions, they are updated continuously to reflect the evolving standard of care. A category of evidence and consensus is assigned to each recommendation in the guidelines. The specific definitions for the NCCN categories for recommendations are found in Table 1 .
Most recommendations contained within the NCCN Guidelines are based upon lower-level evidence and uniform NCCN consensus (category 2A).
1 This is not a deficiency of the guidelines, but is rather because high-level evidence is not available for most decisions across the continuum of care. A deeper look at what constitutes a ''recommendation'' might begin to clarify that issue. A recommendation can include all of the recommended workup, surgical options, options for chemotherapy, and tests recommended for ongoing surveillance. Although many of these options are routinely used as standard of care in clinical practice, there is often not the available body of high-level evidence that supports category 1 recommendations, thus most are category 2A levels of evidence and consensus. In other instances, recommendations for chemotherapy regimens for which there is high-level, randomized clinical trial evidence are listed as category 1.
The NCCN Guidelines are developed and updated at least annually at a panel meeting.
2 Input is solicited from the NCCN member institutions and may also be submitted by industry, non-NCCN clinicians, or patient representatives, or payors. Recommendations from these institutional reviews and outside submissions are discussed by the panel, and if changes are made to the guideline, panel votes are taken and recorded for purposes of transparency. Updated guidelines are published on the NCCN Web site and may be accessed free of charge following registration on the Web site.
Several derivative products arise from the NCCN Guidelines. The NCCN Drugs & Biologics Compendium (NCCN Compendium) is a resource outlining appropriate use of drugs and biologics as recommended in the NCCN Guidelines. To be included in the compendium, an agent must first be recommended in at least 1 of the NCCN Guidelines. The compendium is typically used by clinicians and payors to determine appropriate use and as a standard to determine coverage.
The rapid development and commercialization of biomarker and companion diagnostic testing in cancer gave rise to the NCCN Biomarkers Compendium, to be used by both payors and clinicians to facilitate identification of biomarker tests recommended for use by NCCN guideline panels. The NCCN uses a broad definition of ''biomarker'' for the purposes of this compendium. All tests measuring genes or gene products, which are used for diagnosis, screening, monitoring, surveillance, or for providing predictive or prognostic information, are included in the biomarkers compendium. This compendium focuses on the biology of the biomarker itself and its clinical utility in supporting clinical decision making. Information is organized by the biomarker being measured, and not by listing of commercially available tests or test kits. Close to 1000 biomarker testing recommendations are included in the NCCN Biomarkers Compendium.
The NCCN Biomarkers Compendium contains pointers to the name of the guideline and page where the biomarker recommendation occurs: Disease, Specific Indication (patient subpopulation or disease subtype); Molecular Abnormality (eg, EGFR mutation; (9:11) translocation); Test, which is similar to Molecular Abnormality, but always uses the language of the guideline, eg, HER2 is used in the Test column, while the accepted Gene Symbol, ERBB2, is used in the Molecular Abnormality column; NCCN category of evidence; NCCN recommendation: Clinical Decision (verbatim from guideline where possible); and Notes, which contains other relevant information from the guideline regarding the testing recommendation that does not fit neatly into any other category. Other fields include Gene Symbol and Chromosome for the entity being measured, whether or not this is explicitly contained within the guideline. Idiosyncrasies in nomenclature make this a useful addition to ensure that all tests that focus on a single gene or gene product will all be returned when that Gene Symbol is used to search, whether or not the original guideline material uses this name or another synonym. Methodology and Specimen type are included, where specified, and Test Purpose, which is a brief descriptor from a controlled vocabulary of terms such as diagnostic, prognostic, predictive, surveillance, and monitoring, is included as well.
SEARCHING THE BIOMARKERS COMPENDIUM
The NCCN Biomarkers Compendium is presented on the NCCN Web site as a series of drop-down menus, allowing users to pick from menus listing Guideline, Disease, Molecular Abnormality, or Gene Symbol.
3 Users can retrieve all recommendations for a particular disease, or can select a gene-based search in order to show which diseases have a validated use for a particular gene test. Additional fields can be displayed by selecting from a series of boxes to the right of the drop-down menus (see Figure 1 , which shows default fields for RAS testing in colon cancer). Once records are displayed, the resulting table can be sorted by the information in any of the displayed columns. If a searcher chooses, all records can be displayed and then searched with any text term or sorted by any of the columns for a more comprehensive picture of the contents of the database.
Individual records can be printed as a PDF file. If a record or set of records is selected for printing, output is set so that all fields of information are displayed on a single page (see Figure 2 for one example), which also contains the date when the search was conducted, a necessity as the NCCN Biomarkers Compendium is frequently updated as recommendations for testing are changed and refined.
A summary of the current contents of the NCCN Biomarkers Compendium is shown in Table 2 . As of January 2014, most records are related to protein expression, with more than 550 entries devoted to this type of biomarker. This comprises all recommendations for immunohistochemistry and flow cytometry used to diagnose and phenotype hematologic malignancies and includes 112 different entities as defined by gene symbol. Translocation and mutation testing are the next 2 most frequently recommended types of biomarker testing.
A large number of tests were grouped for the purposes of this simplified table into the category of gross chromosomal abnormalities. Interestingly, the guidelines so far contain only a single recommendation for the use of a gene expression profiling test, and this is the 21-gene reverse transcription-polymerase chain reaction test recommended within the breast cancer treatment guideline, where the score for this test can be used as part of a decision-making process for chemotherapy recommendations in nodenegative, hormone receptor-positive, HER2-negative disease. Table 3 summarizes the biomarker tests included in the NCCN Biomarkers Compendium that are predictive for either responsiveness (eg, BRAF mutation and vemurafenib sensitivity) or nonresponsiveness (eg, KRAS mutation testing and cetuximab or panitumumab insensitivity) to a particular type of therapy. As the number of companion diagnostics and targeted therapies grows, we expect this category of test to become one of the largest categories of testing contained within the Biomarkers Compendium, and it may be surprising to note that only 15 of these types of test are currently recommended within the NCCN Guidelines.
The NCCN Biomarkers Compendium generally avoids recommendations for particular methodologies or test kits to use to assess mutations and translocations. The choice of methodology and supplier for carrying out the recommended biomarker tests remains that of the treating oncologists and pathologists.
The NCCN Biomarkers Compendium may be used by payers as a reference for coverage decisions and by clinicians as a guide to which biomarkers are appropriate to test. The Biomarkers Compendium focuses on the clinical usefulness of biomarker testing rather than specific tests or test kits that identify the presence or absence of the marker. Other groups are continuing to assess clinical and analytic validity for specific biomarker test methodologies. Even the US Food and Drug Administration approval process is limited to clinical and analytic validity, and does not specifically address clinical utility. The NCCN Biomarkers Compendium is complementary to these other efforts. By providing biomarker testing information, the NCCN Biomarkers Compendium aims to ensure that patients have coverage and access to appropriate biomarker testing, based on the evaluations and recommendations of the expert NCCN panel members. 
